CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...

GeneDx Holdings (NASDAQ:WGS) stock is trading higher on Tuesday. The genetic testing company reported a third-quarter EPS ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

The global market for cancer-focused genetic testing services is on a transformative growth trajectory, with projections estimating a market size of USD 8,472.70 million by 2024, and an expected ...

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is ... The region’s market is also driven by the growing number of retail pharmacies and improving ...

Unlike medical providers, genetic testing companies aren’t bound by health privacy laws such as HIPAA despite the health information DNA contains. Even if these companies ostensibly promise to ...

Tempus AI said it agreed to pay $375 million in cash and $225 million in shares to acquire genetic testing company Ambry Genetics. Ambry conducts hereditary cancer screening and currently serves as ...

The chemotherapy drugs 5-FU and capecitabine could harm or kill you if you have a variant in the DPYD gene. Request genetic testing before you take these drugs.

These findings demonstrate disparities in precise genetic diagnosis are not due to diagnostic yields ... GeneDx is at the ...